Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus (NASDAQ:AGEN - Get Free Report) was upgraded by stock analysts at StockNews.com from a "strong sell" rating to a "hold" rating in a report issued on Thursday.

Several other research analysts have also recently issued reports on the stock. B. Riley reiterated a "buy" rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright reaffirmed a "neutral" rating on shares of Agenus in a research note on Tuesday, May 13th. Finally, Robert W. Baird lifted their price target on Agenus from $3.00 to $4.00 and gave the company a "neutral" rating in a research report on Tuesday, May 13th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $9.00.

Agenus Trading Up 4.4%

AGEN traded up $0.16 during trading hours on Thursday, hitting $3.82. The company's stock had a trading volume of 213,540 shares, compared to its average volume of 561,252. The company has a 50-day simple moving average of $2.36 and a 200 day simple moving average of $2.90. The firm has a market capitalization of $104.73 million, a PE ratio of -0.34 and a beta of 1.48. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $19.69.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million. Research analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Barclays PLC lifted its position in Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock worth $90,000 after buying an additional 4,924 shares in the last quarter. Apollon Wealth Management LLC increased its stake in shares of Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 5,000 shares during the last quarter. Corton Capital Inc. purchased a new stake in shares of Agenus during the fourth quarter worth $36,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Agenus by 32.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 15,731 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Agenus during the fourth quarter valued at $51,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.